Diffuse Large B Cell Lymphoma Refractory clinical trials

Explore recruiting diffuse large b cell lymphoma refractory clinical trials.

Recruiting diffuse large b cell lymphoma refractory studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diffuse Large B Cell Lymphoma Refractory trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Denmark, Poland, France, Germany, Spain, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Italy, Germany, Spain, France, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

Italy, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Belgium, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with a Glofitamab-based induction and consolidation concept

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

C5691003_A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) ECHELON-3

Spain, Belgium, Italy, Denmark, Czechia, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Diffuse Large B Cell Lymphoma Refractory trials by city

Diffuse Large B Cell Lymphoma Refractory in Toronto Diffuse Large B Cell Lymphoma Refractory in Vancouver Diffuse Large B Cell Lymphoma Refractory in Montreal Diffuse Large B Cell Lymphoma Refractory in Calgary Diffuse Large B Cell Lymphoma Refractory in Edmonton Diffuse Large B Cell Lymphoma Refractory in Ottawa Diffuse Large B Cell Lymphoma Refractory in Winnipeg Diffuse Large B Cell Lymphoma Refractory in Quebec City Diffuse Large B Cell Lymphoma Refractory in Hamilton Diffuse Large B Cell Lymphoma Refractory in Kitchener Diffuse Large B Cell Lymphoma Refractory in London Diffuse Large B Cell Lymphoma Refractory in Halifax Diffuse Large B Cell Lymphoma Refractory in New York Diffuse Large B Cell Lymphoma Refractory in Los Angeles Diffuse Large B Cell Lymphoma Refractory in Chicago Diffuse Large B Cell Lymphoma Refractory in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease